EVEREST MED (01952) received a 71.2 million share increase from its major shareholder, Kangqiao Capital.

Everest Med (01952) announced that the board of directors was informed by non-executive director, board honorary chairman and main shareholder Mr. Fu Weixin, that from June 16, 2026 to June 17, 2026, Concord Capital (as the main shareholder of the company) purchased 712,000 shares of the company's common stock on the market, at a total cost of approximately HK$19.2 million, with an average price of approximately HK$26.99 per share. Since December 2025, Concord Capital and the directors have purchased over 5,163,000 shares of the company's stock on the market, at a total cost exceeding HK$172.5 million. The board of directors believes that the purchase of shares reflects the strong confidence of the directors and major shareholders in the future prospects and long-term development of the company. Subject to compliance with applicable laws and regulations, Concord Capital and the directors do not rule out the possibility of further increasing their holdings in the company at the appropriate time.